retatrutide phase 2 results 2024 2025 press release New weight-loss drug rivaling bariatric surgery? Here's what the new data actually show. #weightlossjourney #retatrutide #obesity Lilly's triple agonist, retatrutide, delivered

Abstract Background: Growth Hormone Deficiency (GHD) is marked by insufficient growth hormone (GH) production, leading to disruptions in growth and metabolism

Large-scale clinical trials have demonstrated that GLP-1RAs predominantly exhibit neutral or suppressive effects on overall cancer risk, with semaglutide showing no elevated cancer incidence [14], while significant reductions have been observed in specific malignancies, particularly liver cancers and prostate cancers [13, 15]

These include reduction of systolic and diastolic blood pressure, body weight, vascular inflammation, and improvement of endothelial function [55,56,57,58]

Trends Pharmacol Sci 43(8):641652 Kashyap SN, Boyle NR, Roberson ED (2023) Preclinical interventions in mouse models of frontotemporal dementia due to progranulin mutations

84 LabouesseM

Sci Rep 7:41188 Sandoval DA, DAlessio DA (2015) Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease